# Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

> **NCT07199335** · PHASE4 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 100 (estimated)

## Conditions studied

- HIV
- Substance Use Disorder (SUD)
- Injection Drug Use

## Interventions

- **DRUG:** APRETUDE (cabotegravir)

## Key facts

- **NCT ID:** NCT07199335
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-24
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07199335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07199335, "Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07199335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*